We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Premier products in Merck’s portfolio include Keytruda, Gardasil, Winrevair and Bravecto. Outsized contributor Keytruda is an ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.